Preoperative co-application of bevacizumab and tissue plasminogen activator in vitrectomy for proliferative diabetic retinopathy
2024

Bevacizumab and t-PA in Vitrectomy for Diabetic Retinopathy

Sample size: 43 publication 10 minutes Evidence: moderate

Author Information

Author(s): Aras Cengiz, Senturk Fevzi, Erdur Sevil Karaman, Kocabora Mehmet Selim, Dogramaci Mahmut, Burke Cahit, Aras Efe

Primary Institution: Istanbul Medipol University

Hypothesis

Does the co-application of bevacizumab and tissue plasminogen activator improve surgical outcomes in vitrectomy for proliferative diabetic retinopathy?

Conclusion

The co-application of bevacizumab and tissue plasminogen activator shortens surgery time and reduces intraoperative retinal breaks in diabetic retinopathy surgery.

Supporting Evidence

  • The mean surgery time was significantly shorter in the group receiving both medications.
  • The number of iatrogenic retinal breaks was lower in the group receiving both medications.
  • Visual acuity improved significantly in both groups after surgery.

Takeaway

Doctors used two medicines before eye surgery to help patients with diabetes. This made the surgery faster and safer.

Methodology

A prospective, randomized, single-masked, comparative analysis was performed with patients receiving either bevacizumab and t-PA or bevacizumab alone before vitrectomy.

Potential Biases

Possible biased conclusions due to the variability in patient conditions and the single-surgeon approach.

Limitations

The study had a small sample size and potential bias due to the heterogeneity of tractional membranes.

Participant Demographics

40 patients with proliferative diabetic retinopathy, mean age 51.57 years.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.5935/0004-2749.2023-0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication